
Dechra signs £31 million acquisition
pharmafile | September 16, 2016 | News story | Medical Communications | Apex Laboratories, Dechra, acquisition
Dechra has agreed a deal to acquire veterinary pharmaceutical company Australian firm Apex Laboratories for AUS $55 (£31.3) million.
The deal includes the purchase of the company’s business and assets, including its manufacturing site, and will provide Dechra with a direct avenue into the Australian companion animal product market.
“We are delighted to expand our presence in the Australasian market through the acquisition of Apex which has a technically skilled and experienced team,” Dechra chief executive Ian Page said. “Its portfolio offers a range of veterinary licensed products that are complementary to Dechra’s offering, making the business a natural fit within Dechra’s therapeutic portfolio. The facility produces a wide range of dosage forms and has capacity for growth.We believe that the combination of Dechra and Apex are well-placed for continued growth in the Australasian and Asian veterinary pharmaceutical markets.”
Apex manufactures, markets and sells branded non-proprietary prescription and other related companion animal products in Australia and New Zealand. It employs 39 staff and reported revenues of £8.4million last year.
Matt Fellows
Related Content

Brenntag acquires mcePharma to expand GMP capabilities in biopharma services
Brenntag Specialties has acquired Czech-based mcePharma, strengthening its position in the pharma and biopharma industries …

Curium Pharma announces acquisition of Monrol
Curium Pharma, a nuclear medicine company, has acquired Eczacıbaşı-Monrol Nuclear Products (Monrol), a nuclear medicine …

Enosium Life Science acquires RWEality
Enosium Life Science, which specialises in life sciences, has acquired RWEality, a consultancy focused on …






